Literature DB >> 6468486

Intra-individual consistency of prednisolone kinetics during long-term prednisone treatment.

E Langhoff, H Flachs, J Ladefoged, E F Hvidberg.   

Abstract

Eleven patients on long-term prednisone treatment were studied on two occasions separated by 45 to 325 days. In 10 patients the total body clearance of prednisolone only changed about 10%. In one case a 78.5% decrease was observed after stopping treatment with rifampicin and isoniazide. No association was found between the prednisone dose rate (mg/kg per month), patient age or mean endogenous plasma hydrocortisone level and prednisolone clearance/kg. The results indicate considerable intra-individual consistency of prednisolone kinetics if other conditions are not changed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6468486     DOI: 10.1007/bf00543505

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunogassays.

Authors:  A W Meikle; J A Weed; F H Tyler
Journal:  J Clin Endocrinol Metab       Date:  1975-10       Impact factor: 5.958

2.  Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects.

Authors:  M Kozower; L Veatch; M M Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

3.  Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function.

Authors:  G A Buffington; J H Dominguez; W F Piering; L A Hebert; H M Kauffman; J Lemann
Journal:  JAMA       Date:  1976-10-25       Impact factor: 56.272

4.  Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients.

Authors:  F J Frey; W J Amend; F Lozada; B M Frey; N H Holford; L Z Benet
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Oral prednisone for chronic active liver disease: dose responses and bioavailability studies.

Authors:  M Uribe; S W Schalm; W H Summerskill; V L Go
Journal:  Gut       Date:  1978-12       Impact factor: 23.059

6.  Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability.

Authors:  M Davis; R Williams; J Chakraborty; J English; V Marks; G Ideo; S Tempini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

7.  A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone.

Authors:  F J Frey; F Lozada; T Guentert; B M Frey
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

8.  Rifampicin reduces effectiveness and bioavailability of prednisolone.

Authors:  W A McAllister; P J Thompson; S M Al-Habet; H J Rogers
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-19

9.  Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone.

Authors:  F J Frey; W J Amend; F Lozada; B M Frey; L Z Benet
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

10.  Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients.

Authors:  J G Gambertoglio; F Vincenti; N J Feduska; J Birnbaum; O Salvatierra; W J Amend
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

View more
  1 in total

1.  Somatostatin prevents the postoperative increases in plasma amino acid clearance and urea synthesis after elective cholecystectomy.

Authors:  H Heindorff; P Billesbølle; S L Pedersen; R Hansen; H Vilstrup
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.